ILMN
EquityIllumina, Inc.
Health Care · Diagnostics & Research
$129.84
+129.84 (+0.00%)
Open
N/A
Day Range
$129.60 - $132.23
52W Range
$68.70 - $155.53
Volume
602K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $120.24 | N/A | 0.83% | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.60 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.95 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.67 | N/A | 2.83% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.65 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $23.06 | N/A | - | +0.00% |
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
www.illumina.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ILMN
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ILMN.